Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.therap.2020.05.003 http://scihub22266oqcxt.onion/10.1016/j.therap.2020.05.003 32418728!7204680!32418728     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Therapie 2020 ; 75 (4): 355-362 Nephropedia Template TP {{tp|p=32418728|t=2020. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection |pdf=|usr=}}{{32418728}} gab.com Text Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection JO: Therapie http://www.kidney.de/pget.php?&tw=1&pmid=32418728 #FOAvip Non-steroidal anti-inflammatory drugs (NSAIDs) have an optional prescription status that has resulted in frequent use, in particular for the symptomatic treatment of fever and non-rheumatic pain. In 2019, a multi-source analysis of complementary pharmacological data showed that using NSAIDs in these indications (potentially indicative of an underlying infection) increases the risk of a severe bacterial complication, in particular in the case of lung infections. First, the clinical observations of the French Pharmacovigilance Network showed that severe bacterial infections can occur even after a short NSAID treatment, and even if the NSAID is associated with an antibiotic. Second, pharmacoepidemiological studies, some of which minimized the protopathic bias, all converged and confirmed the risk. Third, experimental in vitro and in vivo animal studies suggest several biological mechanisms, which strengthens a causal link beyond the well-known risk of delaying the care of the infection (immunomodulatory effects, effects on S. pyogenes infections, and reduced antibiotics efficacy). Therefore, in case of infection, symptomatic treatment with NSAIDs for non-severe symptoms (fever, pain, or myalgia) is not to be recommended, given a range of clinical and scientific arguments supporting an increased risk of severe bacterial complication. Besides, the existence of a safer drug alternative, with paracetamol at recommended doses, makes this recommendation of precaution and common sense even more legitimate. In 2020, such recommendation is more topical than ever with the emergence of COVID-19, especially since it results in fever, headaches, muscular pain, and cough, and is further complicated with pneumopathy, and given experimental data suggesting a link between ibuprofen and the level of expression of angiotensin-converting enzyme 2. Twit Text FOAVip Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection ????Therapie http://www.kidney.de/pget.php?&tw=1&pmid=32418728 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32418728 #FOAvip English Wikipedia <ref>{{Cite pmid|32418728}}</ref> Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection #MMPMID32418728 Micallef J; Soeiro T; Jonville-Bera AP Therapie 2020[Jul]; 75 (4): 355-362 PMID32418728show ga Non-steroidal anti-inflammatory drugs (NSAIDs) have an optional prescription status that has resulted in frequent use, in particular for the symptomatic treatment of fever and non-rheumatic pain. In 2019, a multi-source analysis of complementary pharmacological data showed that using NSAIDs in these indications (potentially indicative of an underlying infection) increases the risk of a severe bacterial complication, in particular in the case of lung infections. First, the clinical observations of the French Pharmacovigilance Network showed that severe bacterial infections can occur even after a short NSAID treatment, and even if the NSAID is associated with an antibiotic. Second, pharmacoepidemiological studies, some of which minimized the protopathic bias, all converged and confirmed the risk. Third, experimental in vitro and in vivo animal studies suggest several biological mechanisms, which strengthens a causal link beyond the well-known risk of delaying the care of the infection (immunomodulatory effects, effects on S. pyogenes infections, and reduced antibiotics efficacy). Therefore, in case of infection, symptomatic treatment with NSAIDs for non-severe symptoms (fever, pain, or myalgia) is not to be recommended, given a range of clinical and scientific arguments supporting an increased risk of severe bacterial complication. Besides, the existence of a safer drug alternative, with paracetamol at recommended doses, makes this recommendation of precaution and common sense even more legitimate. In 2020, such recommendation is more topical than ever with the emergence of COVID-19, especially since it results in fever, headaches, muscular pain, and cough, and is further complicated with pneumopathy, and given experimental data suggesting a link between ibuprofen and the level of expression of angiotensin-converting enzyme 2. |Angiotensin-Converting Enzyme 2[MESH] |Animals[MESH] |Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects/pharmacology[MESH] |Bacterial Infections/epidemiology/etiology[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/physiopathology[MESH] |France[MESH] |Humans[MESH] |Ibuprofen/administration & dosage/adverse effects/pharmacology[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/drug effects/metabolism[MESH]Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infe(epmc).pdf DeepDyve Pubget Overpricing